Currently breast feeding.
The subject is pregnant or breast feeding
Women who are pregnant or breast-feeding
Pregnant or breast feeding women are excluded from this study
Pregnant or breast-feeding women may not be entered on this study; pregnancy tests must be obtained in girls who are post-menarchal
Pregnancy or breast-feeding
Pregnant or breast-feeding women will not be entered on this study; pregnancy tests must be obtained in girls who are post-menarchal
Women must not be pregnant or breast-feeding
Women must not be pregnant or breast-feeding
Pregnant or breast feeding women
Pregnant or breast-feeding
Patients who are pregnant or breast-feeding
Pregnant, planning a pregnancy or breast feeding during the study
Patients found to be pregnant/breast feeding
Female patients who are pregnant or breast-feeding
ELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C): Women must not be pregnant or breast-feeding
ELIGIBILITY CRITERIA - PHASE II (ARM D): Women must not be pregnant or breast-feeding
Patients who are breast feeding
Pregnant or breast-feeding women
Pregnant or breast-feeding women
Pregnant or breast-feeding females
Pregnant or breast-feeding women, or intending to become pregnant during the study
Pregnant or breast feeding or plans to become pregnant within 6 months of AVB-620 administration.
Not breast feeding at any time during the study.
Pregnant or breast-feeding women.
Not currently pregnant or breast feeding
Women who are pregnant or breast feeding
Woman of childbearing potential that is pregnant or breast-feeding, or planning to become pregnant or breast-feed during protocol treatment and for 3 months after last dose of talimogene laherparepvec
Not breast feeding at any time during the study.
Pregnant or breast feeding females.
Pregnancy or breast-feeding
Women who are pregnant or are breast feeding.
Women who are pregnant or breast-feeding
Pregnant or breast feeding females.
Not breast feeding at any time during the study.
Pregnancy or breast-feeding
Breast feeding or pregnant
Pregnant, planning a pregnancy, or breast feeding
Women must not be breast-feeding
Pregnant women or women who are breast-feeding
Patients who are pregnant or breast-feeding will NOT be eligible for participation
Female patients who are lactating must agree to stop breast-feeding
Patients who are pregnant or breast-feeding
Pregnant or breast feeding.
The participant is pregnant or breast-feeding
The subject is pregnant or breast-feeding
Pregnant or breast feeding
Pregnant or breast feeding females.
Current pregnancy or breast feeding; pregnant women are excluded from this study; breastfeeding should be\r\ndiscontinued in all female subjects
Women who are pregnant or breast feeding.
Pregnancy or breast feeding.
Women who are pregnant or breast-feeding
Pregnant or breast-feeding women.
The participant is pregnant or breast-feeding
Pregnancy or breast-feeding.
Females who are pregnant or breast feeding are excluded since there are unknown teratogenic effects of these agents
Participant is breast feeding or pregnant.
Women who are breast feeding.
Pregnant or breast feeding females (lactating females must agree not to breast feed while taking the study drugs)
Female patients who are pregnant (per institutional practice) or breast-feeding.
A woman who is pregnant, breast-feeding, or planning to become pregnant while enrolled in this study or within 5 months after the last dose of study drug
Pregnant or breast-feeding women
Pregnancy or breast feeding.
Not pregnant or breast feeding
Not breast feeding at any time during the study.
Women who are pregnant or breast-feeding.
Breast feeding
The patient is pregnant or breast feeding.
Women who are pregnant or breast-feeding
Pregnant or nursing women are excluded from this study, breast feeding should be discontinued
Subject is pregnant or breast-feeding.
Women who are pregnant or breast-feeding
Female patients who are pregnant or are breast feeding.
Subject who is pregnant (as confirmed by pregnancy test), planning on becoming pregnant during the follow-up period, or actively breast-feeding; and
Pregnant or breast-feeding women
Pregnant or breast-feeding females
Female subject is pregnant or breast-feeding; lactating females must agree not to breastfeed while taking lenalidomide
Women who are pregnant or breast feeding.
Pregnant or breast feeding
Patients who are pregnant or breast-feeding
Pregnancy or active breast feeding
Pregnant or breast-feeding.
Women who are pregnant or currently breast feeding
Pregnant or breast feeding females
Pregnant or breast-feeding women
Females of child-bearing potential cannot be pregnant or breast-feeding; female participants >= 10 years of age or post-menarchal must have a negative serum or urine pregnancy test within 24 hours prior to beginning treatment; female participants who are breast feeding must agree to stop breast feeding
Pregnant or breast-feeding women
Pregnant and breast-feeding patients are not eligible for the study
Pregnant or breast-feeding
Women may not be pregnant or breast-feeding
Pregnant or breast-feeding females are excluded
Females who are pregnant or breast-feeding
Women who are pregnant or breast-feeding.
Pregnant or breast feeding females (lactating females must agree not to breast feed while taking lenalidomide).
Pregnant or breast feeding.
Pregnancy or breast feeding.
Pregnancy and breast feeding.
Pregnant or breast-feeding women
Women who are nursing must discontinue breast-feeding prior to the enrollment in the trial
Pregnant or breast-feeding females
Women must not be pregnant or breast-feeding
Pregnancy or breast-feeding women
A female patient who is pregnant or breast-feeding
Women who are pregnant or breast-feeding at enrollment
Pregnancy or breast feeding.
Breast feeding or pregnant.
Patients must not be women who are pregnant or breast feeding.
Pregnant or breast-feeding women will not be entered on this study due to risks of fetal and teratogenic adverse events as seen in animal/human studies. Women of childbearing age must obtain a pregnancy test and pregnant or breast feeding females are excluded
Pregnant or breast-feeding women
Women who are pregnant or breast feeding
Pregnant or breast feeding
Pregnant or breast feeding
Pregnancy or mothers who are breast feeding.
Pregnant or breast-feeding woman will not be entered on this study
Pregnant, breast feeding, or planning to become pregnant
Women who are pregnant or breast feeding
The patient is pregnant or breast-feeding
Women who are pregnant or breast-feeding
Pregnancy or breast-feeding within 30 days prior to enrollment
Pregnancy and breast feeding
Pregnant or breast feeding females
Pregnant or breast feeding
Pregnant or breast-feeding females
Female subjects who are pregnant or breast-feeding
Pregnant or breast-feeding
Subject is pregnant, breast-feeding or lactating.
Pregnant or breast-feeding females
Females who are pregnant or breast-feeding
Patient is pregnant or breast-feeding
Pregnant or breast-feeding females.
Pregnant or breast-feeding females.
Women who are pregnant or breast-feeding
Pregnancy or breast-feeding
Women who are pregnant or breast-feeding
Patients who are pregnant or breast feeding
Pregnancy or breast-feeding
Breast feeding after pregnant
Patient is pregnant or breast feeding.
Pregnant or currently breast-feeding
Pregnant or breast feeding
Pregnant or breast feeding
Breast-feeding at screening or planning to become pregnant during the course of therapy
Pregnant or breast feeding
Women who are pregnant or breast-feeding
Women who are pregnant or breast-feeding
Currently pregnant or breast-feeding
Pregnancy or breast-feeding at time of Screening and throughout the study.
Subject is pregnant or breast feeding, or planning to become pregnant within 5 months after the end of treatment
Pregnant or breast feeding females
Pregnant or breast-feeding females
Pregnant and breast-feeding subjects
Pregnant or breast-feeding
Patients must not be pregnant/breast feeding and must agree to practice adequate contraception.
Female patients who are pregnant or breast feeding are not eligible
Patient is pregnant or breast-feeding
Women who are pregnant or breast-feeding
Women who are pregnant or breast-feeding.
Pregnancy or breast-feeding
Women who are pregnant or breast-feeding currently or are planning to do so during or up to 3 months after the end of protocol therapy.
Women who are breast feeding are not eligible
Women who are pregnant or breast-feeding
Breast feeding or pregnant
Pregnant or breast-feeding women
Pregnant or breast feeding
Females who are pregnant, test positive for pregnancy, or are breast-feeding during the Screening period, or intend to become pregnant or breast-feed during the course of the study or within 30 days after last dose of study drug
Pregnancy or breast feeding female
Subject is pregnant or breast feeding, or planning to become pregnant/breastfeed while on study through 5 months after the end of treatment
Women who are breast-feeding or pregnant as evidenced by positive urine pregnancy test done within 72 hours of first dosing
Female patients who are pregnant or breast-feeding
DONOR: Pregnant or breast-feeding
Women who are breast feeding
Pregnant women and women who are breast-feeding
Patient is pregnant or breast-feeding
Pregnant or breast-feeding women
Not breast feeding
DONOR: Not breast feeding
Pregnant or breast-feeding women are excluded
Females who are pregnant, test positive for pregnancy, or are breast-feeding during the Screening period, or intend to become pregnant or breast-feed during the course of the study or within 30 days after last dose of study drug
Pregnant or breast-feeding women are NOT eligible; pregnancy tests must be obtained in females who are post-menarchal
If female, is pregnant or is breast feeding.
Women who are pregnant or breast-feeding
Pregnant or breast feeding
Patient is pregnant or breast-feeding
Breast feeding or pregnant
Pregnancy or breast feeding.
Pregnant or breast feeding females are excluded
Women who are breast-feeding
Breast-feeding at screening or planning to become pregnant during the course of therapy
Women who are pregnant or breast-feeding
Pregnant or currently breast-feeding
Pregnant or breast-feeding
Pregnancy or breast-feeding
Women who are pregnant or breast-feeding
Pregnant, lactating or breast feeding woman
Patient is pregnant or breast-feeding
Pregnant or breast-feeding women.
Pregnant or breast feeding
Pregnancy or breast feeding
Subjects who are pregnant or breast-feeding
Patient is breast feeding.
Women who are pregnant or breast feeding.
Women who are pregnant or breast-feeding
The patient is pregnant or breast-feeding
Pregnant and breast-feeding females
Pregnancy or breast feeding
Women who are pregnant or breast-feeding.
Breast feeding
Breast-feeding, pregnant, or likely to become pregnant during the study
Female participants of child-bearing potential cannot be pregnant or breast-feeding
Pregnant women or women who are breast-feeding
Women that are currently breast feeding
Pregnant women or women who are breast-feeding
Breast feeding women
Pregnancy or breast feeding
Pregnant or breast feeding women due potential damage to the fetus
Pregnant or breast-feeding
Female subjects who are pregnant or breast-feeding, or planning to become pregnant during study treatment and through 3 months after the last dose of study treatment
Breast feeding women
Pregnant, lactating or breast feeding women
Pregnant or breast feeding females
Patient is pregnant or breast-feeding
Pregnant or breast-feeding women will not be entered on this study
Breast feeding and/or pregnant women
Pregnancy or breast feeding
Pregnant or breast-feeding
Women of child-bearing potential who are pregnant or breast feeding
Pregnant or breast-feeding women will not be entered on this study
Pregnant and breast feeding women
Pregnant or breast-feeding women
Female patients who are lactating must agree to stop breast feeding
Pregnancy or breast feeding
Are pregnant or breast-feeding women.
Pregnant or breast-feeding females are excluded
Pregnant or breast feeding females; (lactating females must agree not to breast feed while taking lenalidomide)
Pregnant or breast feeding females
TREATMENT: Pregnant or breast feeding
Pregnancy or breast-feeding
Women who are pregnant or are breast-feeding
Subjects who are breast-feeding and plan to continue breast-feeding during therapy, or have a positive pregnancy test will be excluded from the study; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
Female patients who are lactating must agree to stop breast-feeding
Pregnant or breast-feeding women
Pregnant or breast feeding females
Pregnancy, breast-feeding or planning to become pregnant
Pregnancy or breast-feeding
Pregnancy or breast feeding. Due to the potential teratogenic effects of retinoids, pregnant women are NOT eligible. Breast milk feeding by study patient is NOT allowed
Breast feeding females
Active breast-feeding is also not allowed on study enrollment
Patients who are pregnant or breast-feeding
Pregnancy or unwillingness to stop breast-feeding
Pregnant or breast-feeding patients
Females who are pregnant or breast-feeding
Pregnant or breast-feeding women
Pregnant or breast-feeding females; (lactating females must agree not to breast-feed while taking lenalidomide)
The subject is pregnant or breast-feeding
Relapsed/refractory MCL: Pregnant or breast feeding females
Pregnant or breast feeding (female of child-bearing potential)
Not breast feeding
DONOR: Not breast feeding
DONOR: Pregnant or breast-feeding
Pregnant women or women who are breast-feeding
Pregnant or breast-feeding females; lactating females must agree not to breast-feed while taking lenalidomide
Patients who are pregnant or breast-feeding.
Patients who are pregnant or breast-feeding.
Females who are pregnant or breast-feeding
If female, subject is pregnant or breast-feeding
Female patients who are pregnant or breast-feeding
Pregnant or breast-feeding women
Pregnant or breast-feeding females
Breast feeding (if lactating, must agree not to breast feed while taking pomalidomide)
Patients who are pregnant or breast-feeding
Women of child-bearing potential who are pregnant or breast feeding
Known pregnancy or breast feeding
Pregnant or breast feeding females (lactating females must agree not to breast feed while taking lenalidomide)
Pregnant women or women who are breast-feeding
Pregnant or breast-feeding patients
Known pregnancy or breast-feeding
Pregnant or breast-feeding women are excluded
Pregnant or breast-feeding patients are excluded from this study
Not pregnant or breast-feeding
Female patients who are pregnant or breast-feeding
Pregnancy or breast-feeding
Pregnant or breast feeding
Pregnant or breast-feeding women due to the known birth defects association with the treatments used in this study
Pregnancy or breast feeding
Pregnant or breast-feeding females. (Lactating females must agree not to breast feed while taking lenalidomide).
Patient is pregnant or breast-feeding.
Women who are breast feeding.
Women who are pregnant or breast feeding
Pregnancy or breast feeding.
Pregnancy or breast feeding
Females who are pregnant or breast-feeding.
Women who are pregnant or breast feeding
Pregnancy or breast feeding
Pregnant or breast-feeding
Female patients who are pregnant, breast-feeding, or planning to become pregnant
Pregnant or breast-feeding
Pregnant or breast-feeding
Women who are pregnant or breast-feeding;
Pregnant or breast-feeding.
Women who are pregnant or breast-feeding
Pregnant, planning to become pregnant, or breast feeding.
Breast feeding women.
Female patients who are breast-feeding.
Pregnant or breast-feeding women
Female patients should not be pregnant or breast?feeding
Women who are pregnant or breast-feeding
Female patients must not be pregnant or breast-feeding
Women who are pregnant or breast feeding.
Be female and pregnant or breast feeding.
Subject is pregnant or breast feeding, or planning to become pregnant within 5 months after the end of treatment
Pregnant or breast feeding
Pregnancy or breast-feeding
Individuals who are pregnant or breast feeding or who become pregnant while enrolled on this trial will be excluded from participation
Pregnant or breast feeding females.
Pregnant or breast feeding women are excluded from this study
Pregnant or breast feeding
Women who are actively breast feeding
Pregnant or breast feeding
Women who are nursing must discontinue breast-feeding prior to the enrollment in the trial
Pregnancy or breast feeding
Women who are breast feeding
Participants cannot be breast feeding
Pregnancy or breast feeding
Breast feeding women are not eligible
For women of childbearing potential, no pregnancy or breast-feeding
-  Pregnant or breast-feeding women
Pregnant or breast-feeding
Female patients who are pregnant or breast feeding
Female patients who are pregnant or breast-feeding
Women who are pregnant or breast-feeding
Pregnant or breast-feeding patients
Pregnancy or breast feeding
Female who is pregnant or breast feeding and HCV treatment requires use of ribavirin
Pregnant or breast-feeding women, due to the unknown effects of GI-6207 on the fetus or infant
Breast feeding women
Pregnancy or breast feeding
Pregnant or breast-feeding females
Pregnant or breast-feeding females
Patients known or found to be pregnant or who is unwilling to stop breast-feeding
Patients who are pregnant or breast-feeding
Pregnancy or breast feeding
Females who are pregnant or breast-feeding
Women who are pregnant or breast feeding
Women who are pregnant or breast feeding
Women who are pregnant or breast-feeding
Pregnant or breast feeding females
Pregnant or breast-feeding females
Pregnant or breast-feeding (lactating) women or women who plan to become pregnant or breast-feed during the study
Currently breast feeding.
Women who are pregnant or breast-feeding
Pregnant or breast feeding female patient
They are pregnant or breast feeding.
Patients that are pregnant, breast feeding, or unwilling to use effective contraception during the study
Female participant who is pregnant or breast-feeding
Patients who are pregnant or breast-feeding
Patients who are pregnant or breast feeding
Is pregnant or breast-feeding
Subject is pregnant or breast-feeding. Women must not breast-feed until at 5 months after completion of study participation..
Currently pregnant or breast-feeding
The patient is pregnant or breast feeding.
Pregnant or breast-feeding females
Female participants who are lactating, breast feeding, or pregnant.
Female subject who is pregnant or breast-feeding, or any subject expecting to conceive or father a child during this study;
Non pregnant, non-breast feeding females under active contraception
Pregnant or breast-feeding
Patients who are breast-feeding
Pregnancy or breast feeding mother
Pregnant or breast-feeding females or females who intend to become pregnant during study participation.
Female patients who are pregnant or breast feeding are not eligible
Women must not be pregnant or breast-feeding
Pregnant or breast-feeding females
Pregnant or breast-feeding women.
Women who are pregnant or breast feeding.
Pregnant or breast feeding women
Pregnancy or breast feeding.
Subject is pregnant or breast feeding
Women who are pregnant or breast-feeding
Pregnant or breast feeding
Pregnant or breast-feeding females
Women who are pregnant or breast feeding; women with a positive pregnancy test on enrollment or prior to study drug administration
Pregnancy or breast feeding
Pregnant or breast-feeding females; (lactating females must agree not to breast feed while taking lenalidomide)
Pregnant or breast-feeding women
Female subjects who are pregnant or breast feeding
Women who are either breast feeding or pregnant.
Currently pregnant or breast-feeding, or planning to become pregnant during study treatment and through 3 months after the last dose of study treatment
Pregnancy or breast feeding
Women who are pregnant or breast-feeding.
Pregnant or breast-feeding
Subject is pregnant or breast feeding
Women who are pregnant (including positive pregnancy test at enrollment or prior to study drug administration) or breast-feeding
Breast-feeding women
Patients who are pregnant or breast-feeding.
Pregnancy or breast feeding
Pregnant or breast-feeding females
Women who are pregnant or breast feeding are not to be included.
Pregnancy or breast feeding
Pregnant or breast feeding patients
Females must not be pregnant or breast-feeding
Pregnant or breast-feeding women
Pregnant or lactating/breast-feeding women.
Women of child-bearing potential who are pregnant or breast feeding
Subjects are pregnant or breast-feeding at entry.
Pregnant or breast-feeding females
Pregnancy and breast feeding
Female patients who are pregnant or breast-feeding, or intends to become pregnant during the study
Females who are pregnant or breast feeding are not eligible for this study
The patient is pregnant or breast feeding.
Females who are breast-feeding or pregnant
Women who are pregnant or breast feeding
Not pregnant or breast-feeding
Pregnant or breast-feeding women will not be entered on this study; women of child-bearing age must obtain a pregnancy test, and pregnant or breast feeding females are excluded
Subject is pregnant, planning on becoming pregnant during the follow-up period, or actively breast-feeding;
Women who are pregnant or breast-feeding
Pregnancy or breast-feeding
Is pregnant or breast-feeding
Pregnant or breast feeding at time of consent
Patient is pregnant or breast-feeding.
Pregnant or breast feeding females
Participant is pregnant or breast feeding.
Women must not be pregnant or breast-feeding
Pregnant or breast-feeding females
Pregnant or breast feeding
Patient is pregnant or breast-feeding
Patients who are pregnant or breast-feeding
Female subject is pregnant or breast-feeding
A female patient who is pregnant or breast-feeding
Pregnant or breast feeding females
Pregnant or breast-feeding females; patients who become pregnant during active therapy will be immediately removed from the study
Women who are pregnant or breast-feeding
Female participants pregnant or breast-feeding
Pregnant or breast-feeding patients
Pregnant or breast-feeding
Female subject is pregnant or breast-feeding, or planning to become pregnant during study treatment and through 3 months after the last dose of talimogene laherparepvec
The subject is pregnant or breast-feeding
If female, patient is pregnant or breast-feeding.
Pregnant or breast-feeding female patients;
Patients who are pregnant or breast-feeding are not eligible for this study; negative pregnancy tests must be obtained in female patients who are postmenarchal
Women who are pregnant or breast feeding
Women who are breast feeding
Females who are pregnant or breast-feeding
Women who are pregnant or breast-feeding
Breast feeding or pregnant
Pregnant or breast-feeding female patients
Female patients who are lactating must agree to stop breast-feeding
Breast feeding or pregnant.
Pregnant, lactating, or breast feeding women
Pregnancy or breast-feeding women
Women who are pregnant or breast-feeding
Breast feeding or pregnant
Women who are pregnant or breast-feeding
Women who are pregnant or breast feeding
Subjects who are pregnant or breast feeding.
Patients who are currently pregnant, planning to become pregnant, or breast-feeding
Pregnant or breast feeding females
Pregnant or breast-feeding
Pregnant or breast-feeding women.
Women who are breast feeding or pregnant as evidenced by positive serum pregnancy test.
Lactating women who are breast-feeding
Female participants pregnant or breast-feeding
Women who are pregnant or breast feeding
Breast feeding women.
Pregnant patients or currently breast-feeding
Patient is pregnant or breast feeding, or planning to become pregnant within 5 months after the end of treatment
Pregnant or breast feeding females
Patients who are pregnant or breast-feeding
Pregnant or breast-feeding patients
Patients who are pregnant or breast-feeding
Pregnancy or breast-feeding
Pregnant patients or women who are breast-feeding (patients must be postmenopausal)
Patients who are pregnant or breast-feeding
Women who are pregnant or breast-feeding
Patients who are pregnant or breast feeding are NOT eligible for participation
Pregnant or breast-feeding females
Women who are pregnant or breast-feeding.
Female patients who are pregnant or breast-feeding
Pregnancy or breast feeding
Women of child-bearing potential who are pregnant or breast feeding.
Pregnant or breast-feeding women
Female patients who are pregnant or breast-feeding
Pregnant or breast feeding females; (lactating females must agree not to breast feed while taking pomalidomide)
Breast feeding females
Pregnant or breast-feeding
Females who are pregnant or breast feeding
Pregnant or breast-feeding; pregnancy testing will be performed on all menstruating females within 14 days prior to study enrollment
Pregnant women or women who are breast-feeding
Female patients who are pregnant or breast feeding
Female patient pregnant or breast feeding
Pregnant or breast-feeding
Breast feeding (Female only)
DONOR: Breast feeding (Female only)
Women of childbearing potential who are pregnant or breast feeding.
Female patients who are pregnant or breast-feeding
Female participants who were breast feeding or pregnant.
Pregnant or breast feeding females; (lactating females must agree not to breast feed while taking lenalidomide)
For women only - currently pregnant or breast feeding.
Patients who are breast-feeding
Pregnant or breast-feeding women
Patients who are pregnant or breast-feeding will NOT be eligible for participation
Pregnancy or breast-feeding women
Pregnant or breast feeding females.
Pregnant (positive serum pregnancy test) or breast feeding
Pregnancy or breast-feeding.
Female subject is pregnant or breast-feeding
Pregnant women or women who are breast-feeding
Pregnant or breast-feeding; pregnancy testing will be performed on all menstruating females within 14 days prior to study enrollment
Female patients who are pregnant or breast feeding
Pregnant or breast feeding women
Pregnant or breast feeding females.(Lactating females must agree not to breast feed while taking lenalidomide).
Pregnant, inadequate contraception, breast feeding
Lactating or breast feeding females
Women who are pregnant or breast-feeding
Pregnant or breast feeding
Pregnant or breast feeding women
Pregnant or breast feeding
Pregnant or breast-feeding females
Pregnant or breast feeding females are not eligible
Females who are pregnant or breast-feeding
Breast feeding must be discontinued
Pregnant or breast-feeding females; (lactating females must agree not to breast feed while taking Revlimid)
Pregnant or breast feeding females; (lactating females must agree not to breast feed while taking lenalidomide or azacitidine)
Pregnant or breast feeding females (lactating females must agree not to breast feed while taking lenalidomide)
Female patients who are pregnant or breast-feeding
Pregnant or breast feeding
A woman who is pregnant or breast feeding
Women who are pregnant or breast-feeding
Pregnancy or breast feeding.
Female patients who are pregnant or breast feeding
Pregnancy or breast feeding
Females who are pregnant or are breast-feeding.
Breast feeding women;
Pregnant women; breast feeding should be discontinued during treatment
Patient is pregnant or breast feeding or expecting to conceive or father children within the projected duration of the study, because of the potential for serious adverse reactions in nursing infants from vorinostat, breast feeding must be discontinued for the duration of therapy with vorinostat
Pregnant or breast feeding females; (lactating females must agree not to breast feed while taking lenalidomide)
Pregnant or breast feeding women
For females, if they are pregnant or breast-feeding
Pregnant or intending to become pregnant or breast-feeding patents
Breast feeding
Pregnant or breast-feeding women are excluded
Pregnant (positive pregnancy test) or breast feeding
Pregnant or breast-feeding women are ineligible
Female subject is pregnant or breast-feeding.
Pregnancy or breast-feeding
Pregnant or breast-feeding female
Women who are pregnant or breast feeding.
Subject who is pregnant or breast feeding
Pregnant or breast feeding females; (lactating females must agree not to breast feed while taking ibrutinib or idelalisib)
Pregnant women or women who are breast-feeding
Women who are pregnant or breast-feeding.
Pregnant or breast-feeding patients.
Pregnant or breast feeding
Subject is pregnant or breast feeding, or planning to become pregnant within 7 months after the end of treatment.
Patients who are pregnant or breast-feeding
Pregnant or breast-feeding
Is pregnant or breast-feeding
Women who are breast-feeding or pregnant.
Pregnant or breast feeding
Pregnant or breast-feeding
Women who are pregnant or breast-feeding.
Women who are pregnant or breast-feeding
Pregnant, lactating or breast feeding women
Pregnancy or breast-feeding.
Subjects who are pregnant or are breast-feeding
Women currently pregnant or breast feeding.
Pregnant or breast-feeding women are excluded.
Females who are breast-feeding or pregnant
Pregnant or breast-feeding women
Women who are pregnant or breast-feeding
Pregnant or breast-feeding
Pregnancy or breast feeding
Women who are pregnant or breast-feeding
Female participants who are breast-feeding
Pregnant (positive serum pregnancy test) or breast feeding
Patients may not be pregnant or breast feeding
Pregnant or breast feeding females
are pregnant or breast-feeding.
Are pregnant and or breast feeding.
Pregnancy or breast-feeding
Breast feeding or pregnant females
Pregnancy or breast-feeding
Women who are breast feeding or pregnant as evidenced by pregnancy test.
Female patients who are pregnant or breast feeding
Pregnancy or breast feeding
If female, is pregnant or breast-feeding;
Female participants who are pregnant, lactating, or breast-feeding
Pregnant women and women who are breast-feeding
Breast-feeding women
Breast feeding or pregnant females
Patients who are pregnant or breast-feeding.
Pregnancy or breast-feeding.
If female, is lactating or breast feeding
Women who are pregnant or breast feeding.
Pregnant or breast feeding
Pregnant or breast-feeding women
Subjects who are pregnant or breast feeding.
Pregnant or breast feeding within the projected duration of trial participation through 4 months after the last dose of study treatment.
Pregnant or breast feeding women
Is pregnant or breast feeding
Pregnant or breast feeding females (lactating females must agree not to breast feed while taking lenalidomide)
Female patients who are pregnant or breast-feeding. All post menarche female patients must have a pregnancy test at screening.
Breast feeding females
Currently pregnant or breast-feeding.
Women who are pregnant or breast feeding.
Pregnant or breast-feeding females
Pregnant or breast feeding
Women who are pregnant or breast-feeding
Women who are pregnant or breast feeding are not to be included.
Pregnant women or women presently breast-feeding
Pregnant or breast feeding
Women who are pregnant or breast feeding
Pregnant or breast-feeding females.
Breast feeding
Pregnancy/Breast feeding
Not breast feeding
DONOR: Not breast feeding
Subjects in their reproductive age who are breast feeding or have a positive pregnancy test
Patient is breast feeding
Not breast feeding
Pregnant or breast-feeding women will not be entered on this study
Pregnancy or breast-feeding.
Pregnant or breast-feeding
Women who are pregnant or breast-feeding.
Is pregnant or breast-feeding
Pregnancy or breast-feeding.
Women of childbearing potential who are pregnant or breast feeding.
Pregnant or breast feeding
Pregnant or breast feeding
Pregnant or breast feeding females; (lactating females must agree not to breast feed while taking lenalidomide)
Pregnant, lactating or actively breast feeding females.
Breast feeding women
Pregnant or breast feeding females (lactating females must agree not to breast feed while taking ipilimumab)
Pregnancy or breast-feeding
Pregnant or breast feeding females; lactating females must agree not to breast feed while taking lenalidomide
Pregnant or breast feeding
Pregnant and/or breast-feeding women.
Pregnant or breast feeding
Pregnant or breast-feeding women
Females in the study must not be pregnant or breast feeding and not planning to become pregnant or breast feed for the duration of the study, and for at least three months after study completion
Pregnancy or breast-feeding.
Pregnant or breast-feeding women will not be entered on this study due to risks of fetal and teratogenic adverse events.
The patient is pregnant or breast feeding.
Breast feeding females
Subjects who are pregnant or are breast-feeding.
Women who are pregnant or breast-feeding
Women who are pregnant or breast-feeding
Lactating females who are actively breast feeding.
Not breast feeding
DONOR: Not breast feeding
Pregnant or breast-feeding females
Patients who are pregnant or breast-feeding
Pregnant or breast-feeding women.
Pregnant or breast-feeding women
Pregnant or breast feeding.
Pregnant or breast feeding
Pregnancy or breast-feeding
Women of child-bearing potential who are pregnant or breast feeding
Pregnancy or breast feeding
Pregnant or breast-feeding
Not pregnant or breast-feeding
Pregnancy or breast feeding.
Women who are currently pregnant or breast-feeding
Pregnant or breast feeding females; (lactating females must agree not to breast feed while taking lenalidomide)
Female patients who are lactating must agree to stop breast-feeding
pregnant or breast feeding
Pregnancy or breast feeding
Patients must not be pregnant or breast feeding and must practice adequate contraception
Patient is pregnant or nursing/breast-feeding.
Pregnant or breast feeding
Pregnant or breast-feeding.
Subject is pregnant or breast feeding, or planning to become pregnant within 5 months after the end of treatment
Pregnant or breast-feeding, or planning to become pregnant during study treatment and within 2 months after the last administration of investigational product.
Women who are pregnant or breast feeding.
If you are pregnant or breast feeding
Pregnant or breast-feeding females
Pregnant or breast-feeding (lactating) women or women who plan to become pregnant or breast-feed during the study
Patient is pregnant or breast-feeding
Women who are pregnant or breast feeding
Women who are pregnant, become pregnant, or are breast-feeding
Women who are currently breast-feeding are not eligible for this study
Currently pregnant or breast-feeding
Female patients who are pregnant or breast-feeding
Breast feeding women.
Pregnant or breast feeding
Must not be pregnant or breast feeding
Females who are pregnant or might be pregnant or are breast-feeding
Women who are pregnant or breast feeding will not be included in the study
May not be pregnant, lactating or breast feeding
Current pregnancy and breast feeding
Not pregnant or breast?feeding
Pregnancy or breast feeding
Pregnant or breast feeding
Pregnancy or breast feeding
Pregnant or breast-feeding
Pregnant and/or breast feeding if a female recipient
Pregnant or breast feeding
Patients who are pregnant or breast feeding
Females who are pregnant or breast feeding
Pregnant and breast-feeding women are ineligible
Females who are pregnant, breast-feeding or intending to become pregnant; this exclusion criterion will be assessed by questioning the patient about the pregnancy status, breast-feeding status, the intent to become pregnant, the menopausal status, and the date of the last menstrual period
Women who are pregnant or breast feeding
Lactation or breast feeding.
Pregnant or breast feeding
Pregnant women or women who are breast feeding are not eligible for the study
Pregnant or breast-feeding.
Females who are pregnant or breast feeding at the time of screening will not be eligible for this study
Subject is not pregnant or breast feeding, and cannot become pregnant within 30 days after the end of treatment
Subject is pregnant or breast feeding, or planning to become pregnant within 5 months after end of treatment
Pregnant or breast feeding females
Pregnant or breast feeding females
Pregnant patients or actively breast-feeding
Women who are currently pregnant or breast feeding
Pregnant or breast feeding
Subject is pregnant (documented by a positive pregnancy test according to hospital standard practices) or is actively breast-feeding.
(Female only) Breast feeding
Pregnant or breast-feeding women
Pregnancy or breast feeding
At the beginning of the study, pregnant women and women who are breast-feeding will not be enrolled
CONTROL (HEALTHY) GROUP: At the beginning of the study, pregnant women and women who are breast-feeding will not be enrolled
Breast feeding
Women must be one year from pregnancy and breast-feeding
Women currently pregnant or breast-feeding at time of study consent
Participants who have a positive pregnancy test, are pregnant, or breast feeding
Pregnant or breast feeding
Pregnant and/or breast-feeding
Pregnancy or breast feeding
Patient is pregnant or breast-feeding
Pregnancy/breast feeding: females who are pregnant or breast feeding at the time of study entry are not eligible
Women who are pregnant or breast-feeding
Patients who are pregnant, planning pregnancy, or breast feeding
Not be currently pregnant or breast feeding
Pregnant or breast-feeding
Women who are pregnant or breast-feeding
Breast feeding women
Pregnant, planning to become pregnant starting from 28 days prior to receiving CC-486 throughout your participation in the study, and for at least 90 days following your last dose of study treatment, or breast-feeding females
Pregnancy or breast-feeding.
Pregnant or breast feeding
Women who are currently pregnant or breast-feeding
Pregnant or breast feeding
Breast feeding
Is pregnant or breast feeding
Female patients who are pregnant or breast feeding
Female subjects must not be pregnant or breast feeding within 6 months prior to and during course of study
Women must not be pregnant or breast-feeding
Pregnant women or those who are breast feeding
Children, minors, pregnant women, women who are breast feeding, institutionalized patients
Known pregnancy or breast-feeding
Patient must NOT be pregnant or breast-feeding
Women that are pregnant or breast-feeding
Not pregnant or breast feeding
Pregnant, lactating, or breast feeding women
Women who are pregnant or breast-feeding
Patients who are currently pregnant or breast feeding; a pregnancy test within 72 hours of the first PET/MRI will be performed
Women who are pregnant or breast-feeding
Breast feeding / pregnancy
Pregnant or currently breast-feeding
Breast-feeding
Pregnant women or women who are breast-feeding
Pregnant women or women who are breast feeding
Known pregnancy or breast-feeding
Women who are pregnant of breast-feeding
Women who are pregnant or breast feeding
Breast feeding/pregnancy
Breast-feeding
Pregnancy or lactating with the intent of breast feeding
Subjects who are pregnant or breast feeding
No breast-feeding
Known pregnancy or breast-feeding
Not pregnant or breast-feeding
Not pregnant or breast feeding
Patient Volunteers/Contrast Enhancement Sub-group: Not pregnant or breast-feeding
Breast feeding
Pregnant or breast-feeding
Pregnancy or breast feeding
Female patients cannot be pregnant or breast feeding
OVARIAN CANCER PARTICIPANTS: Patient is pregnant or breast-feeding
BREAST CANCER PARTICIPANTS: Patient is pregnant or breast-feeding
Women who are pregnant or breast-feeding
Not breast-feeding, if applicable
Women who are either pregnant or breast feeding
Pregnant or breast-feeding women
Pregnancy or breast-feeding
Pregnant or breast feeding.
Pregnant or breast-feeding females
Female pregnant or breast feeding
Patients who are pregnant or are breast feeding
Patients who are pregnant, breast-feeding or are planning to become pregnant during the study duration
Is breast-feeding or pregnant
pregnancy or breast-feeding
Subjects who are pregnant or breast feeding
Women must not be pregnant or breast-feeding
Pregnant or breast feeding female patient
Pregnant or breast feeding women
The patient is pregnant or breast feeding
Women who are pregnant or breast feeding
Pregnant or breast-feeding
Pregnant women or women who are breast feeding
Participant is pregnant or breast-feeding
Patients who are breast feeding
Pregnancy and contraception: Subjects who are pregnant, breast-feeding or planning to conceive within 30 days are not eligible
Pregnant or breast feeding women
Patient is pregnant or breast feeding, or planning to become pregnant while enrolled in the study, up to the End of Study visit
Pregnant or breast feeding
Female subject is pregnant or breast-feeding, or planning to become pregnant during study treatment and through 3 months after the last dose of talimogene laherparepvec.
Patient is pregnant or breast feeding, or planning to become pregnant while enrolled in the study, up to the End of Study visit
Patient is pregnant or breast-feeding.
Pregnant or breast-feeding women will not be entered on this study; women of child-bearing age must obtain a pregnancy test and pregnant or breast feeding females are excluded
